Vincristine Side Effects With Concomitant Fluconazole Use During Induction Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.
Child
Humans
Fluconazole
/ adverse effects
Vincristine
Induction Chemotherapy
/ adverse effects
Retrospective Studies
Hyponatremia
/ chemically induced
Antifungal Agents
/ adverse effects
Mycoses
/ drug therapy
Drug-Related Side Effects and Adverse Reactions
/ etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ complications
Journal
Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
01
08
2022
accepted:
01
01
2023
medline:
28
9
2023
pubmed:
11
3
2023
entrez:
10
3
2023
Statut:
ppublish
Résumé
As a mainstay of treatment for acute lymphoblastic leukemia (ALL), vincristine's side effect profile is well known. Parallel administration of the antifungal fluconazole has been shown to interfere with the metabolism of vincristine, potentially resulting in increased side effects. We conducted a retrospective chart review to determine whether concomitant administration of vincristine and fluconazole during pediatric ALL induction therapy impacted the frequency of vincristine side effects, namely, hyponatremia and peripheral neuropathy. We also evaluated whether the incidence of opportunistic fungal infections was impacted by fluconazole prophylaxis. Medical charts of all pediatric ALL patients treated with induction chemotherapy at Children's Hospital and Medical Center in Omaha, NE, from 2013 to 2021 were retrospectively reviewed. Fluconazole prophylaxis did not significantly impact the rate of fungal infections. We found no correlation between fluconazole use and increased incidence of hyponatremia or peripheral neuropathy, which supports the safety of fungal prophylaxis with fluconazole during pediatric ALL induction therapy.
Identifiants
pubmed: 36897660
doi: 10.1097/MPH.0000000000002637
pii: 00043426-990000000-00191
doi:
Substances chimiques
Fluconazole
8VZV102JFY
Vincristine
5J49Q6B70F
Antifungal Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e861-e866Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83–103.
Survival rates for childhood leukemias. Accessed March, 2020. https://www.cancer.org/cancer/leukemia-in-children/detection-diagnosis-staging/survival-rates.html
Yeh TC, Liu HC, Hou JY, et al. Severe infections in children with acute leukemia undergoing intensive chemotherapy can successfully be prevented by ciprofloxacin, voriconazole, or micafungin prophylaxis. Cancer. 2014;120:1255–1262.
Yang L, Yu L, Chen X, et al. Clinical analysis of adverse drug reactions between vincristine and triazoles in children with acute lymphoblastic leukemia. Med Sci Monit. 2015;21:1656–1661.
Gubbins PO. Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450. Expert Opin Drug Metab Toxicol. 2011;7:1411–1429.
Moriyama B, Henning SA, Leung J, et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses. 2012;55:290–297.
Teusink AC, Ragucci D, Shatat IF, et al. Potentiation of vincristine toxicity with concomitant fluconazole prophylaxis in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2012;29:62–67.
Eiden C, Palenzuela G, Hillaire-Buys D, et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J Pediatr Hematol Oncol. 2009;31:292–295.
Pfaller M, Messer S, Gee S, et al. In vitro susceptibilities of candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J Clin Microbiol. 1999;37:870.
Macedo D, Leonardelli F, Dudiuk C, et al. Molecular confirmation of the linkage between the rhizopus oryzae CYP51A gene coding region and its intrinsic voriconazole and fluconazole resistance. Antimicrob Agents Chemother. 2018;62:e00224–18.
Pekpak E, İleri T, İnce E, et al. Toxicity of vincristine combined with posaconazole in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2018;40:e309–e310.
Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001;18:137–142.
Bermúdez M, Fuster JL, Llinares E, et al. Itraconazole-related increased vincristine neurotoxicity: case report and review of literature. J Pediatr Hematol Oncol. 2005;27:389–392.
Jain S, Kapoor G. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine. Pediatr Blood Cancer. 2010;54:783.
Ariffin H, Omar KZ, Ang EL, et al. Severe vincristine neurotoxicity with concomitant use of itraconazole. J Paediatr Child Health. 2003;39:638–639.
van Schie RM, Brüggemann RJ, Hoogerbrugge PM, et al. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. J Antimicrob Chemother. 2011;66:1853–1856.
Yang QY, Hu YH, Guo HL, et al. Vincristine-induced peripheral neuropathy in childhood acute lymphoblastic leukemia: genetic variation as a potential risk factor. Front Pharmacol. 2021;12:771487.
Salvador C, Salvador R, Willeit P, et al. Hyponatremia during induction therapy in distinct pediatric oncological cohorts: a retrospective study. Front Oncol. 2021;11:708875.
van de Velde ME, Kaspers GL, Abbink FCH, et al. Vincristine-induced peripheral neuropathy in children with cancer: a systematic review. Crit Rev Oncol Hematol. 2017;114:114–130.
Janczar S, Zalewska-Szewczyk B, Mlynarski W. Severe hyponatremia in a single-center series of 84 homogenously treated children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2017;39:e54–e58.
Seetharam S, Thankamony P, Gopakumar KG, et al. Higher incidence of syndrome of inappropriate antidiuretic hormone secretion during induction chemotherapy of acute lymphoblastic leukemia in indian children. Indian J Cancer. 2019;56:320–324.
Triarico S, Romano A, Attinà G, et al. Vincristine-induced peripheral neuropathy (VIPN) in pediatric tumors: mechanisms, risk factors, strategies of prevention and treatment. Int J Mol Sci. 2021;22:4112.
Carlson K, Ocean AJ. Peripheral neuropathy with microtubule-targeting agents: Occurrence and management approach. Clin Breast Cancer. 2011;11:73–81.
Lavoie Smith EM, Li L, Hutchinson RJ, et al. Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. Cancer Nurs. 2013;36:E49–E60.